medicationPrescription only (US)Escitalopram is an approved medicine; the cited literature reports trial outcomes, not dosing advice.
EscitalopramBenefits, Dosage & Interactions
Also known as: Lexapro
Escitalopram is a medication classified as a selective serotonin reuptake inhibitor (SSRI). It is primarily used to treat major depressive disorder (MDD) in adults and adolescents aged 12 years and older, and generalized anxiety disorder (GAD) in adults. It is typically taken in the morning.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 658 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
658 human randomized trials and regulatory approval on file.
Plasma half-life
27–32 h
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Escitalopram in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Escitalopram entry is written from. Each number matches an inline marker above.
- [1]Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical TrialHoge EA, Bui E, Mete M, et al. · JAMA Psychiatry · 2023 · Peer-reviewed · PMID 36350591
- [2]Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysisYin J, Song X, Wang C, et al. · BMC Psychiatry · 2023 · Peer-reviewed · PMID 38001423
How to track Escitalopram doses
Tracking Escitalopram well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Escitalopram with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is morning. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Escitalopram through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 27 h, effects and timing shifts show up over days rather than instantly. Review Escitalopram alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Escitalopram dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Escitalopram?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Escitalopram is a medication classified as a selective serotonin reuptake inhibitor (SSRI). It is primarily used to treat major depressive disorder (MDD) in adults and adolescents aged 12 years and older, and generalized anxiety disorder (GAD) in adults. Escitalopram is the S-enantiomer of the racemic mixture citalopram, meaning it is the active component responsible for citalopram's therapeutic effects. The medication is available by prescription only and comes in oral tablet and solution forms. It is known by various brand names, most notably Lexapro. (FDA label, DrugBank)
What does the research say about Escitalopram?
Tap a section to expand.
Escitalopram exerts its antidepressant and anxiolytic effects primarily by selectively inhibiting the reuptake of serotonin (5-HT) into presynaptic neurons in the central nervous system. Serotonin is a neurotransmitter involved in regulating mood, emotion, sleep, and appetite. By blocking its reuptake, escitalopram increases the concentration of serotonin in the synaptic cleft, leading to enhanced serotonergic neurotransmission. This increase in serotonin levels is thought to help regulate mood and alleviate symptoms of depression and anxiety. Unlike some other antidepressants, escitalopram has very weak or no affinity for other neurotransmitter receptors, such as adrenergic, dopaminergic, histaminergic, cholinergic, or GABA receptors, which contributes to its relatively favorable side effect profile. The full therapeutic effects of escitalopram are not immediate and typically take several weeks to manifest as the brain adapts to the altered serotonin levels. (FDA label, DrugBank, PubChem)
Source for this section: Sources for How does Escitalopram work?: Jumps to this entry in the sources and references list at the end of the page.
Escitalopram is used to treat mental health conditions by addressing imbalances in brain chemistry. Its primary benefits include:
* **Treatment of Major Depressive Disorder (MDD):** Escitalopram has demonstrated efficacy in reducing symptoms of MDD, including persistent sadness, loss of interest or pleasure, changes in appetite or sleep, fatigue, feelings of worthlessness, and suicidal thoughts. Clinical trials have shown its superiority over placebo in improving depressive symptoms in adults and adolescents. (FDA label)
* **Treatment of Generalized Anxiety Disorder (GAD):** It is effective in treating GAD, characterized by excessive, uncontrollable worry about various events or activities. Escitalopram helps to alleviate symptoms such as restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbance associated with GAD. (FDA label)
* **Relatively well-tolerated:** Compared to some older antidepressants, escitalopram is generally considered to have a more favorable side effect profile, making it a common first-line treatment option. (MedlinePlus)
It is important to note that the benefits are usually observed after several weeks of consistent use, as the brain gradually adapts to the medication's effects.
The efficacy of escitalopram for the treatment of Major Depressive Disorder (MDD) has been established in multiple placebo-controlled clinical trials in adults and a 10-week, flexible-dose, placebo-controlled clinical trial in adolescent patients aged 12 to 17 years. These trials consistently demonstrated that escitalopram was significantly more effective than placebo in improving symptoms of depression as measured by standardized rating scales (e.g., Montgomery-Asberg Depression Rating Scale [MADRS], Hamilton Depression Rating Scale [HAM-D]). For Generalized Anxiety Disorder (GAD), the efficacy of escitalopram has also been established in adult trials. Studies showed improvement in measures such as the Hamilton Anxiety Rating Scale (HAM-A) in patients treated with escitalopram compared to placebo. Long-term studies have also supported its role in maintaining remission and preventing relapse in both MDD and GAD. (FDA label, Cochrane)
Common side effects associated with escitalopram are generally mild to moderate and often subside with continued use. These may include:
* Nausea
* Insomnia or somnolence (drowsiness)
* Diarrhea or constipation
* Dry mouth
* Increased sweating
* Sexual dysfunction (e.g., decreased libido, delayed ejaculation, anorgasmia)
* Fatigue
* Dizziness
* Headache
More serious, but less common, side effects include:
* **Serotonin Syndrome:** A potentially life-threatening condition characterized by agitation, hallucinations, rapid heart rate, fever, muscle rigidity, gastrointestinal symptoms, and rapid changes in blood pressure. This risk is increased when escitalopram is taken with other serotonergic drugs.
* **QT Prolongation and Torsade de Pointes:** Escitalopram can cause dose-dependent prolongation of the QT interval, which can increase the risk of serious ventricular arrhythmias. Patients with pre-existing heart conditions or those taking other QT-prolonging medications are at higher risk.
* **Hyponatremia:** Low sodium levels in the blood, particularly in elderly patients or those taking diuretics, can occur.
* **Increased bleeding risk:** SSRIs can impair platelet aggregation, increasing the risk of bleeding, especially when taken with blood thinners or NSAIDs.
* **Activation of Mania/Hypomania:** In some individuals, particularly those with undiagnosed bipolar disorder, escitalopram can precipitate manic or hypomanic episodes.
* **Seizures:** Escitalopram should be used with caution in patients with a history of seizure disorders.
* **Withdrawal Symptoms (SSRI Discontinuation Syndrome):** Abrupt discontinuation can lead to symptoms like dizziness, sensory disturbances (e.g., 'electric shock' sensations), sleep disturbances, agitation, anxiety, tremor, and sweating. Gradual tapering under medical supervision is recommended.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Several warnings and precautions are associated with escitalopram use:
* **Suicidality Risk:** Antidepressants, including escitalopram, carry a black box warning from the FDA regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) with major depressive disorder and other psychiatric disorders. Close monitoring is essential, especially during initial treatment and dose adjustments. (FDA label)
* **Serotonin Syndrome:** Be vigilant for symptoms of serotonin syndrome, especially when co-administered with other serotonergic agents (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, St. John's Wort). (FDA label, MedlinePlus)
* **QT Prolongation:** Use with caution in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure, and in those taking other drugs that prolong the QT interval. (FDA label)
* **Discontinuation Syndrome:** Do not stop escitalopram abruptly. A gradual dose reduction is recommended to minimize withdrawal symptoms. (FDA label, MedlinePlus)
* **Abnormal Bleeding:** Use with caution in patients taking aspirin, NSAIDs, warfarin, or other anticoagulants due to an increased risk of bleeding. (FDA label)
* **Activation of Mania/Hypomania:** Prescribe with caution to patients with a history of mania. Screening for bipolar disorder is recommended before initiating treatment. (FDA label)
* **Seizures:** Use with caution in patients with a history of seizure disorder. (FDA label)
* **Angle-Closure Glaucoma:** SSRIs, including escitalopram, can cause pupillary dilation, which can trigger an angle-closure attack in susceptible individuals. (FDA label)
* **Hyponatremia:** Monitor for symptoms of low sodium, especially in elderly patients or those on diuretics. (FDA label)
* **Renal and Hepatic Impairment:** Dose adjustment may be necessary in patients with severe renal impairment or hepatic impairment. (FDA label)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Escitalopram is contraindicated in the following situations:
* **Concomitant use with Monoamine Oxidase Inhibitors (MAOIs):** Concurrent use or use within 14 days of discontinuing an MAOI (including linezolid and intravenous methylene blue) is contraindicated due to the risk of serotonin syndrome. Conversely, an MAOI should not be started within 14 days of discontinuing escitalopram. (FDA label)
* **Hypersensitivity:** Individuals with known hypersensitivity to escitalopram or citalopram or any of the excipients in the formulation should not use it. (FDA label)
* **Concomitant use with Pimozide:** Coadministration with pimozide, an antipsychotic medication, is contraindicated due to the risk of QT prolongation and potential for cardiac arrhythmias. (FDA label)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Combining escitalopram with certain substances can lead to dangerous interactions:
* **Monoamine Oxidase Inhibitors (MAOIs):** Absolutely avoid combining with MAOIs (e.g., phenelzine, tranylcypromine, isocarboxazid, selegiline, linezolid, intravenous methylene blue) due to a severe risk of serotonin syndrome, which can be fatal. A washout period of at least 14 days is required between stopping an MAOI and starting escitalopram, and vice versa. (FDA label)
* **Other Serotonergic Drugs:** Exercise extreme caution or avoid combining with other drugs that increase serotonin levels, such as triptans (for migraines), other SSRIs, SNRIs (serotonin-norepinephrine reuptake inhibitors), tricyclic antidepressants (TCAs), fentanyl, lithium, tramadol, buspirone, amphetamines, St. John's Wort, and tryptophan supplements. This combination significantly increases the risk of serotonin syndrome. (FDA label)
* **Pimozide:** Concomitant use is contraindicated due to the risk of QT prolongation and cardiac arrhythmias. (FDA label)
* **QT-Prolonging Drugs:** Avoid coadministration with other medications known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics, fluoroquinolone antibiotics). This interaction increases the risk of serious ventricular arrhythmias. (FDA label)
* **Anticoagulants and Antiplatelet Agents:** Combining with warfarin, aspirin, NSAIDs (e.g., ibuprofen, naproxen), or other antiplatelet drugs increases the risk of bleeding events, including gastrointestinal hemorrhage. (FDA label)
* **Alcohol:** While not a direct contraindication for all, alcohol can exacerbate central nervous system depressant effects and worsen symptoms of depression or anxiety. It is generally advised to avoid or limit alcohol consumption. (MedlinePlus)
* **CYP2C19 and CYP3A4 Inhibitors:** Certain medications that inhibit these enzymes can increase escitalopram levels, potentially leading to increased side effects. Conversely, inducers of these enzymes can decrease escitalopram levels. (FDA label)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Escitalopram is typically taken once daily, in either the morning or the evening. It can be taken with or without food. The specific timing and whether to take it with or without food does not significantly impact its absorption or effectiveness, offering flexibility based on individual preference and how it affects sleep (if it causes drowsiness or insomnia). The medication has a half-life of approximately 30 hours. The dose is user-directed and must be set by a licensed clinician. (FDA label, MedlinePlus)
Source for this section: Sources for When should you take Escitalopram?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Escitalopram?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
| Phenelzine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Tranylcypromine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Selegiline | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Rasagiline | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| 5-HTP | Avoid | Compound pairConfidence: theoretical | 5-HTP raises serotonin and layered onto an SSRI/SNRI risks serotonin syndrome.Source pending | Avoid combining 5-HTP with prescription serotonergic antidepressants. |
| L-Tryptophan | Caution | Compound pairConfidence: theoretical | Additional serotonin precursor with an SSRI/SNRI can push serotonin too high.Source pending | Do not combine without a prescribing clinician's guidance. |
| St John's Wort | Avoid | Compound pairConfidence: theoretical | St John's Wort has serotonergic activity and induces CYP3A4, altering SSRI levels.Source pending | Avoid combining. |
Frequently asked questions about Escitalopram
Escitalopram is a medication. It is also known as Lexapro. What follows is drawn from peer-reviewed literature indexed on PubMed, FDA label text where a label exists, and NIH reference records.
Escitalopram is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Escitalopram, it is typically taken in the morning and its approximate half-life is 27 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Escitalopram carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Escitalopram is a medication, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Escitalopram is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 27 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Escitalopram with no sign-up.
Combining a medication like Escitalopram with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Escitalopram: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 27 hours, once-daily dosing is the usual pattern for Escitalopram. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 27 hours, a single missed dose of Escitalopram usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Escitalopram the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Escitalopram?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial(opens PubMed in a new tab)JAMA Psychiatry · 2023 · PMID 36350591 · https://pubmed.ncbi.nlm.nih.gov/36350591/
- 2.Trial of Psilocybin versus Escitalopram for Depression(opens PubMed in a new tab)N Engl J Med · 2021 · PMID 33852780 · https://pubmed.ncbi.nlm.nih.gov/33852780/
- 3.The clinical pharmacokinetics of escitalopram(opens PubMed in a new tab)Clin Pharmacokinet · 2007 · PMID 17375980 · https://pubmed.ncbi.nlm.nih.gov/17375980/
- 4.Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis(opens PubMed in a new tab)BMC Psychiatry · 2023 · PMID 38001423 · https://pubmed.ncbi.nlm.nih.gov/38001423/
- 5.A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?(opens PubMed in a new tab)Int Clin Psychopharmacol · 2014 · PMID 24424469 · https://pubmed.ncbi.nlm.nih.gov/24424469/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 146571(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/146571
Verify at
Publisher search links for Escitalopram. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Escitalopram?
Plain-text summary, safe to quote verbatim:
Escitalopram is a medication classified as a selective serotonin reuptake inhibitor (SSRI). It is primarily used to treat major depressive disorder (MDD) in adults and adolescents aged 12 years and older, and generalized anxiety disorder (GAD) in adults. It is typically taken in the morning.
Source: DoseRoutine — https://doseroutine.com/library/escitalopram
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Escitalopram — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/escitalopram
What compounds are similar to Escitalopram?
Others in the medication category or studied for the same goals.